Pulmoz: a wearable bioimpedance-sensing patch for remote pulmonary function assessment in ALS

Active Grant Awarded

Award ID
R41NS143559
Recipient
Awarding agency
Obligated
$472,228

Award facts

Completion date 9% complete
Place of performance
Lebanon, NH 03766, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute of Neurological Disorders and Stroke, awarded Rytek Medical Inc. a grant of $472,228 on September 17, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds PULMOZ, a wearable bioimpedance-sensing patch for remote pulmonary function assessment in patients with amyotrophic lateral sclerosis (ALS). The project addresses limits of standard pulmonary function tests, including inaccurate data in patients with bulbar weakness, dependence on patient cooperation, and inability to assess continuously or frequently. The underlying electrical impedance technique passes a weak, non-ionizing current through a belt of surface electrodes around the chest and derives simple pulmonary metrics from the resulting images. The recipient reports good correlation between impedance-derived metrics and pulmonary function in ALS patients, and notes that existing imaging systems require a bulky bedside instrument. Place of performance is Lebanon, New Hampshire 03766. The ultimate completion date is July 31, 2028. The source identifies no sub-recipients. The parent program supports extramural research on the fundamental structure and function of the brain and nervous system.

Description

Abstract
Respiratory weakness is a common manifestation of many neuromuscular diseases, including amyotrophic lateral sclerosis (ALS), myasthenia gravis, guillain-barre syndrome, and certain muscular dystrophies. Standard pulmonary function tests (PFTS) suffer from several limitations. These include: 1. Inability to obtain accurate data in patients with concomitant bulbar weakness 2. Reliance on the patient being able to cooperate effectively; 3. Inability to obtain continuous assessment, especially when the patient is in the intensive care unit; 4. Inability to obtain data more frequently, especially as needed for ventilation monitoring or for end-stage patients no longer able or interested in performing PFTS. One approach that offers a potentially more effective means for monitoring pulmonary function is via the application of electrical impedance (EI) sensing. A technique that leverages EI sensing to image the thorax involves placing a belt embedded with multiple surface electrodes around the chest; a low-resolution image is obtained by passing a very weak, non-ionizing electrical current between varying sets of electrodes and measuring the resulting voltages. Real-time videos of breathing can be obtained with the patient at rest breathing comfortably and also with full inspiration and expiration. From these images, simple metrics of pulmonary function can be derived. The technology has already found use in critical care patients with a variety of disorders and is very safe, IT is even being used in premature infants to help monitor pulmonary condition and lung maturation. Our group has specifically shown good correlation between impedance-derived metrics and pulmonary function in patients with ALS when using this EI imaging technology. However, EI imaging typically requires a bulky bedside instrument, complex computation for image formation, and an electrode belt that must be wrapped around the entire chest limiting its use to in-clinic acquisition with trained personnel to support belt placement. In this phase I sttr proposal, our plan is to develop pulmoz, a new wearable EI system to serve as a convenient, non-fatiguing, and novel tool capable of providing quantitative assessment in a remote setting of pulmonary function in patients with ALS. In specific aim 1, we plan to model and develop a basic electrode array patch and system for remote ALS pulmonary function assessment. In specific aim 2, we will conduct a human subjects study to guide the design of and test a compact electrode array for pulmonary function evaluation with comparison to standard pulmonary function measures. By the end of this study, we aim to have designed a prototype wearable EI system and demonstrated feasibility of acquiring robust pulmonary function data in patients with ALS, opening the door to its wide application in the acute and chronic care of patients across a range of neuromuscular diseases.

Quick answers

Who received award R41NS143559?

R41NS143559 was awarded to Rytek Medical Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 17, 2026.

How much is award R41NS143559 worth?

$472,228 has been obligated on R41NS143559.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award